[1] Gennaro D,Alberto M,Mario D,et al.Clinical states of cirrhosis and competing risks[J].J Hepatol,2018,68(3):563-576.
[2] Wu XN,Xue F,Zhang N,et al.Global burden of liver cirrhosis and other chronic liver diseases caused by specific etiologies from 1990 to 2019[J].BMC Public Health,2024,24(1):363-363.
[3] 喻灿,周雅君,李瀚旻,等.基于“补肾生髓成肝”法则治疗肝硬化血小板减少的临床观察[J].中西医结合肝病杂志,2023,33(10):890-893.
[4] 刘皎皎.“补肾生髓成肝”改善肝癌肝再生微环境治疗晚期肝癌的临床疗效观察及机制研究[D].湖北中医药大学,2021.
[5] 郑嵘炅,邓泽润,韩丹,等.骨髓间充质干细胞来源外泌体调节大鼠肝细胞凋亡的机制[J].中国组织工程研究,2024,28(1):44-49.
[6] Zhang Z,Shang J,Yang Q,et al.Exosomes derived from human adipose mesenchymal stem cells ameliorate hepatic fibrosis by inhibiting PI3K/Akt/mTOR pathway and remodeling choline metabolism[J].J Nanobiotechnol,2023,21(1):29.
[7] Sun S,Yang H,Xin J,et al.Transcriptomics confirm the establishment of a liver-immune dual-humanized mouse model after transplantation of a single type of human BMSC[J].Liv Intern,2023,43(6):1345-1356.
[8] Ding Y,Chang C,Niu Z,et al.Overexpression of transcription factor Foxa2 and Hnf1α induced rat bone mesenchymal stem cells into hepatocytes.[J].Cytotechnology,2016,68(5): 2037-2047.
[9] Yang B,Luo Q,Wang N,et al.HPF modulates the differentiation of BMSCs into HLCs and promotes the recovery of acute liver injury in mice[J].Intern J Mol Sci,2023,24(6):5686-5686.
[10] Ahn YJ,Yun WS,Choi JS,et al.Biodistribution of poly clustered superparamagnetic iron oxide nanoparticle labeled mesenchymal stem cells in aminoglycoside induced ototoxic mouse model[J].Biomed Engineer Lett,2021,11(1):1-15.
[11] Zhao S,Liu Y,Pu Z.Bone marrow mesenchymal stem cell-derived exosomes attenuate D-GaIN/LPS-induced hepatocyte apoptosis by activating autophagy in vitro[J].Drug Des Dev Ther,2019,13:2887-2897.
[12] Fang CH.The role of bone marrow stem cells (BMSCs) in liver repair[J].J Stem Cell Res Ther,2021,11(6):1.
[13] 陈泽山,蓝红妮,张明琪,等.间充质干细胞抗肝纤维化的调控机制[J].中华中医药学刊,2022,40(6):177-181.
[14] Feng Y,Li Y,Xu M,et al.Bone marrow mesenchymal stem cells inhibit hepatic fibrosis via the AABR07028795.2/rno-miR-667-5p axis[J].Stem Cell Res Ther,2022,13(1):375.
[15] Zhang R,Li W,Jiang X,et al.Ferulic acid combined with bone marrow mesenchymal stem cells attenuates the activation of hepatic stellate cells and alleviates liver fibrosis[J].Front Pharmacol,2022,13:863797.
[16] Liu Z,Zhou S,Zhang Y,et al.Rat bone marrow mesenchymal stem cells (BMSCs) inhibit liver fibrosis by activating GSK3β and inhibiting the Wnt3a/β-catenin pathway[J].Infect Agents Cancer,2022,17(1):17.
[17] Yasmine KH,Ghada MM,Wahid SM,et al.Bone marrow-derived mesenchymal stem cell potential regression of dysplasia associating experimental liver fibrosis in albino rats.[J].Biomed Res Intern,2019,2019:5376165.
[18] 韦冬珏,张凤英,周莹,等.中医药联合干细胞抗肝纤维化的思路与进展[J].中华中医药学刊,2019,37(1):76-81.
[19] 刘莹,周晓玲,谢胜,等.济生肾气汤对干细胞移植后肝硬化大鼠干细胞归巢能力的影响[J].世界华人消化杂志,2015,23(7):1104-1109.
[20] 刘莹,周晓玲,谢胜,等.济生肾气汤联合骨髓间充质干细胞移植对肝硬化大鼠T淋巴细胞亚群及红细胞免疫功能的影响研究[J].中国全科医学,2015,18(36):4501-4505.
[21] 韦宛华.“补肾生髓法”基于SDF-1/CXCR4轴促进骨髓间充质干细胞移植治疗肝硬化的机制研究[D].广西中医药大学,2019.
[22] 潘益巧.“补肾化瘀法”基于SDF-1/CXCR4轴促进骨髓间充质干细胞移植治疗肝硬化的机制研究[D].广西中医药大学,2021.
[23] 阮博文.“补肾生肝法”促EPO分泌对骨髓间充质干细胞移植治疗肝硬化机制的研究[D].广西中医药大学,2021.
[24] 李裕珍.基于PI3K/AkT/mTOR信号通路探讨补肾生髓法促进骨髓间充质干细胞移植治疗肝硬化的机制研究[D].广西中医药大学,2021.
[25] 周晓玲,王月明,吴腾,等.基于SDF-1/CXCR4轴观察济生肾气汤对肝硬化大鼠BMSCs归巢的影响[J].中国比较医学杂志,2022,32(8):11-18.
[26] 王月明.基于PI3K/AKT/HIF-1α信号通路探讨温肾化瘀法治疗肝硬化的作用机制[D].广西中医药大学,2022.
[27] 张万成,刘永刚,席奇,等.常占杰教授运用“水气理论”治疗肝硬化腹水经验[J].中西医结合肝病杂志,2023,33(2):157-159.
[28] 陈佳美,慕永平,刘平.“病-方(效)-证”的研究实践与创新发展(二)——一贯煎治疗肝硬化的方证病理学基础探析[J].上海中医药大学学报,2023,37(2):1-6,21.